These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28989282)

  • 1. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.
    Fragkos KC
    Clin Exp Gastroenterol; 2017; 10():229-240. PubMed ID: 28989282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea.
    Brenner DM; Dove LS; Andrae DA; Covington PS; Gutman C; Chey WD
    Neurogastroenterol Motil; 2018 Mar; ():e13331. PubMed ID: 29575372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R; Staller K
    Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
    Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
    Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.
    Barshop K; Staller K
    Ther Adv Chronic Dis; 2017 Nov; 8(11):153-160. PubMed ID: 29090081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
    Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
    N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study.
    Vijayvargiya P; Breen-Lyles M; Nord SL; Maselli D; Busciglio I; Boinpally R; Muslin A; Carrothers TJ; Camilleri M
    Dig Dis Sci; 2022 Aug; 67(8):3911-3921. PubMed ID: 35122592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
    Lacy BE
    Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
    Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.
    Brenner DM; Sayuk GS; Abel JL; Burslem K
    J Manag Care Spec Pharm; 2021 Apr; 27(4):469-477. PubMed ID: 33769858
    [No Abstract]   [Full Text] [Related]  

  • 14. Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis.
    Qin D; Tao QF; Huang SL; Chen M; Zheng H
    Front Pharmacol; 2022; 13():757969. PubMed ID: 35281934
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel Therapies in IBS-D Treatment.
    Nee J; Zakari M; Lembo AJ
    Curr Treat Options Gastroenterol; 2015 Dec; 13(4):432-40. PubMed ID: 26432092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
    Keating GM
    Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
    Sobolewska-Włodarczyk A; Włodarczyk M; Storr M; Fichna J
    Ther Clin Risk Manag; 2016; 12():771-5. PubMed ID: 27257381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
    Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
    Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
    Scarpellini E; Laterza L; Ianiro G; Tack J; Abenavoli L; Gasbarrini A
    Expert Opin Pharmacother; 2016 Jul; 17(10):1395-402. PubMed ID: 27267380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials.
    Lacy BE; Harris LA; Chang L; Lucak S; Gutman C; Dove LS; Covington PS; Lembo A
    Therap Adv Gastroenterol; 2019; 12():1756284819841290. PubMed ID: 31019552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.